Samson Tom
President and CEO, Co-Founder

ST Photo v1.jpg

Dr. Tom became the President and Chief Executive Officer of Britecyte in June 2022.  He is an experienced business, science, and clinical leader with more than 20 years of innovative experience in the development and commercialization of advanced biologics, drugs, devices, and tissue-based products.  Prior to joining Britecyte, Dr. Tom was the Vice President for Kelly Science & Clinical, the second-ranked life sciences staffing provider in the United States.  Previously, Dr. Tom was the President and Chief Executive Officer of Osiris Therapeutics, a leader in the regenerative medicine space.  In 2019, he managed the company’s acquisition by Smith+Nephew, a global medical technology business.  Dr. Tom has also held key leadership positions at other medical technology companies including Bioventus, Ethicon (a Johnson & Johnson company), and Vion Pharmaceuticals.  He is an author on more than 30 issued patents, patent applications, and scientific publications describing first-in-class products, including Prochymal®, the world's first approved drug with a stem cell as its active ingredient.

 

Dr. Tom earned a BA degree in Biology and Chemistry from Cornell University, MS and PhD degrees in Biochemistry from the University of Rochester School of Medicine and Dentistry, and an MBA degree in General Management from the Johns Hopkins University Carey Business School.  He is a certified Project Management Professional (PMP®), Risk Management Professional (PMI-RMP®), and Strategic Project Leader (SPL®).